ALTSTATION.IO

Abbott Laboratories (ABT) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$109.29

Change

+0.19%

Market Cap

$190.21B

Avg Volume

8.6M

Company Overview

Abbott Laboratories, headquartered in Abbott Park, Illinois, specializes in healthcare products across various sectors. Its product lineup includes medical devices, nutritional products, diagnostic tools, and established pharmaceuticals. Hospitals, clinics, and pharmacies are typical customers, with offerings ranging from blood glucose monitoring systems to infant formula and cardiac devices. Their wide array of products caters to diverse needs, from chronic disease management to essential nutritional support.

Abbott is a strong player in the healthcare market, particularly in medical devices where it often ranks among the top competitors. Its edge comes from extensive research and development capabilities, robust product pipelines, and a well-recognized brand. Key competitors include Medtronic and Johnson & Johnson, which impact Abbott’s market share. Potential threats stem from pricing pressures in the healthcare sector and the rapid pace of technological advancements, compelling Abbott to stay innovative to maintain its lead.

Currently, Abbott is in a growth phase, focusing on expanding its medical device segment and launching new products. The company reported a 9.1% year-over-year increase in revenue in its most recent quarterly earnings. Significant milestones include the successful rollout of its continuous glucose monitors and diagnostic testing solutions during the pandemic, which have bolstered its position in key markets. Overall, Abbott is poised for sustained growth, leveraging its diverse portfolio and commitment to innovation.

Key Financials

Market Cap

$190.21B

Revenue

$44.33B

EBITDA

$11.49B

Gross Margin

56.7%

Profit Margin

14.7%

Revenue Growth

4.4%

Total Cash

$7.73B

Total Debt

$12.97B

Free Cash Flow

N/A

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

29.38

Forward P/E

17.52

Beta

0.75

52-Week High

$141.23

52-Week Low

$105.27

EPS

$3.72

50-Day Avg

$121.48

200-Day Avg

$128.74

Price/Book

3.73

Technical Analysis

Over the past 52 weeks, Abbott Laboratories (ABT) has shown a downward trend, declining approximately 14.0% from its recent peak, which was around $140 in February. Key resistance levels are identified near $130, where the price has had multiple rejections, while support is visible around $110.83, which served as a pivot point during the latest decline. A notable head-and-shoulders formation can be observed from March through November, indicating a bearish reversal pattern. In recent weeks, the stock has struggled to gain momentum, hovering near the current price of $109.29, which places it just above the support level and suggests potential vulnerability for further drops if this level is breached. Overall, ABT’s current price is close to the lower end of its 52-week range, indicating that sentiment remains weak, with a likelihood of continued selling pressure if broader market conditions do not improve.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for Abbott Laboratories (ABT) stock in the past week (February 1 – February 7, 2026):

1. Positive Clinical Data for Atrial Fibrillation Treatments and New Stroke Risk Device

Abbott announced positive late-breaking clinical results on February 6, 2026, for two of its atrial fibrillation (AFib) treatment systems: the Volt™ Pulsed Field Ablation (PFA) System and the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™. The Volt PFA System demonstrated an 84.2% success rate in treating paroxysmal AFib and nearly 68% for persistent AFib at 12 months. Additionally, early results from the VERITAS Study showed clinically meaningful closure rates for the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation implant designed to reduce stroke risk in patients with non-valvular AFib, achieving 93.9% complete LAA closure by 45 days.

2. Director Purchases Over $1 Million in ABT Stock

On February 4, 2026, Abbott Laboratories Director Daniel Starks purchased 10,000 shares of ABT stock at an average price of $108.73 per share, totaling over $1 million. This transaction increased his direct ownership in the company by 0.15%, signaling insider confidence.

Market Sentiment and Analyst Recommendations

Bull Case

Abbott’s medical device division is firing on all cylinders. The Volt PFA System hit 84.2% success rates for paroxysmal AFib and the Amulet 360 LAA Occluder achieved 93.9% closure rates — these are genuinely competitive results that address massive addressable markets. Q4 2025 device revenue grew 10.4% organically, proving this isn’t theoretical upside. The stock has fallen 17.4% over 12 months while the company guides 6.5% to 7.5% organic growth for 2026 and 10.3% EPS growth, which means valuation has compressed into an attractive entry point. Director Starks bought $1 million in stock at $108.73 on February 4th — insiders don’t buy into sinking ships. The Exact Sciences acquisition will materially expand cancer diagnostics, a high-margin growth vector. At 29.38 P/E with 10%+ EPS growth expected, ABT is cheaper than its historical average despite stronger fundamentals.

Bear Case

The FreeStyle Libre glucose sensor recall linked to seven deaths is a serious regulatory problem that could expand. Abbott’s nutrition business is genuinely broken — Q4 2025 missed estimates and 2026 guidance came in soft, which matters because this segment historically carried margins. The stock is down 14% in 30 days and sitting just above support at $110.83, suggesting technical capitulation isn’t finished. Revenue growth of 4.4% is pedestrian for a company trading at 29.38 P/E, and if the nutrition business continues deteriorating or if device growth slows, that multiple becomes indefensible. The chart shows a textbook head-and-shoulders formation from March through November, a bearish reversal pattern. Net debt of $5.24 billion ($12.97B debt minus $7.73B cash) limits financial flexibility if execution stumbles further.

What to Watch

Monitor Q1 2026 earnings for three things: whether device growth sustains above 10%, whether nutrition guidance stabilizes or deteriorates further, and the trajectory of FreeStyle Libre recall costs. Watch the $110.83 support level closely — a break below that opens the door to $105.27, the 52-week low. The Exact Sciences acquisition closing timeline and integration updates matter significantly for cancer diagnostics credibility. Analyst price targets are spread wide ($113 to $158), so any major clinical data misses or device growth disappointments could trigger downgrades that accelerate selling. Track whether Abbott can guide 2026 organic growth above 7% at the next earnings call; anything below 6% suggests the bull case is weakening. The $130 resistance level is where the stock needs to prove it can hold; repeated rejections there would confirm the downtrend remains intact.

Analyst Consensus

BUY

Based on 24 analyst opinions

Low Target

$113.00

Mean Target

$133.11

High Target

$158.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

115,000

Earnings & Dividends

Next Earnings

Apr 15, 2026

EPS (Trailing)

$3.72

Dividend Yield

231.0%

Payout Ratio

63.4%

Frequently Asked Questions

Is ABT a good stock to buy?

Abbott Laboratories (ABT) has a strong analyst recommendation with a “BUY” rating and a target price of $133.11. Given its current price of $109.29, there’s potential for upside, making it an attractive option for investors.

What is ABT’s price target?

The average price target for Abbott Laboratories is $133.11. This represents a potential upside of about 21.8% from the current price of $109.29.

Does ABT pay a dividend?

Yes, Abbott Laboratories offers a dividend yield of 231.0%. This makes it an appealing choice for income-focused investors looking for consistent cash flow.

What is ABT’s P/E ratio?

Abbott’s current P/E ratio stands at 29.38, while the forward P/E is more attractive at 17.52. This suggests that the stock may be fairly valued or even undervalued with growth expectations considered.

What has been ABT’s 52-week price range?

ABT’s 52-week price range is between $105.27 and $141.23. This shows that the stock has experienced some volatility but remains within a reasonable range for potential investors.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.